According to IQVIA figures, US sales of Lexiscan were approximately $650 million for the 12 months that ended 31st March 2022, making it one of Astellas' top products.

Astellas has won a reprieve in its attempt to stop Pfizer's generic medicines unit Hospira launching a copycat version of its pharmacologic stress agent Lexiscan in the US – but only for a ...